Zai Lab to Present Zoci Data From Ongoing Phase 1 Trial at AACR Annual Meeting

MT Newswires Live04-18

Zai Lab (ZLAB) said Friday data from its ongoing phase 1 trial of zocilurtatug pelitecan showed a 53.7% intracranial objective response rate in patients with small cell lung cancer and brain metastases.

The findings, which showed that the zoci drug candidate triggers intracranial lesion regression and reduced tumor size, will be presented at the American Association for Cancer Research Annual Meeting in San Diego, according to a statement.

The potential zoci drug conjugate also demonstrated a manageable safety profile, with most adverse events reported as low grade, the company said.

The company's phase 1b/2 trial data also showcased antitumor activity in patients with extrapulmonary neuroendocrine carcinomas, with an objective response rate of 38.2%, according to the company.

Price: 24.06, Change: +0.56, Percent Change: +2.38

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment